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Background: Trivalent inactivated flu vaccines (TIV) are currently the best means to prevent influenza infections.
However, the protection provided by TIV is partial (about 50%) and it is needed to improve the efficacy of
protection. Since the respiratory tract is the main site of influenza replications, a vaccine that triggers mucosal
immunity in this region can potentially improve protection against this disease. Recently, PapMV nanoparticles used
as an adjuvant in a formulation with TIV administered by the subcutaneous route have shown improving the
immune response directed to the TIV and protection against an influenza challenge.
Findings: In the present study, we showed that intranasal instillation with a formulation containing TIV and PapMV
nanoparticles significantly increase the amount of IgG, IgG2a and IgA in lungs of vaccinated mice as compared to
mice that received TIV only. Instillation with the adjuvanted formulation leads to a more robust protection against
an influenza infection with a strain that is lethal to mice vaccinated with the TIV.
Conclusions: We demonstrate for the first time that PapMV nanoparticles are an effective and potent mucosal
adjuvant for vaccination.
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Vaccination with trivalent inactivated flu vaccines (TIV)
remains the most affordable and efficient way to control
diseases caused by influenza virus. The TIV is reformu-
lated on the recommendation of WHO at the beginning
of every year based on the circulating strains of the virus
in the population. From that point, the manufacture
process takes up to 8 months before the release the vac-
cine [1]. During this period, strains change through anti-
genic drift and shift and consequently, contribute to the
decrease of vaccine effectiveness.
The TIV are currently administered by the intramus-
cular route, which is not optimal for protection to an in-
fluenza infection that occurs in the respiratory tract. The* Correspondence: denis.leclerc@crchudequebec.ulaval.ca
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in the respiratory tract is the intranasal route [2,3]. How-
ever, the TIV was previously showed to be less immuno-
genic by the intranasal route [4,5]. The amount of antigen
needed to trigger IgA production by this route must be in-
creased by two fold which, directly impact the number of
available doses [4,5]. Therefore, changes in the vaccine
formulation to improve TIV efficacy in the respiratory
tracts and increase the number of doses are needed [6].
Development of mucosal adjuvants that can improve
both, the immune response to TIV in lungs and dose
sparing became a priority [5,7,8]. Current available adju-
vants are ineffective in inducing mucosal immunity be-
cause they cannot be administered by the intranasal
route due to their biophysical properties. As an example,
aluminium hydroxide, the most commonly used adju-
vant in vaccines, is inefficient with TIV and cannot be
used by the mucosal route [9]. New safe and potent ad-
juvants are therefore needed.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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mosaic virus (PapMV) nanoparticles to be used as a
mucosal adjuvant. This hypothesis is supported by a pre-
vious report by our group showing that PapMV nano-
particles can trigger innate immunity in lungs of mice
[10]. Instillation with PapMV nanoparticles triggered
pro-inflammatory cytokines and chemokines secretion
and immune cells recruitment shortly after treatment
[10]. PapMV nanoparticles were also showed to be a
TLR7 ligand, a receptor that activates innate immunity
[11]. Furthermore, PapMV nanoparticles administered
by the subcutaneous route were previously shown to im-
prove and broaden the immune response to TIV in
mouse and ferret animal models [7].
The objective of this study was to demonstrate that
PapMV nanoparticles are able to induce mucosal im-
munity against TIV when administered by the intranasal
route, in order to show its potential as a mucosal adju-
vant. This route of administration was compared with




PapMV nanoparticles were kindly provided by Folia Bio-
tech Inc. (lot # L-5728, Quebec City, Canada). Those
PapMV nanoparticles are comparable to a lot used in
previous studies [10]. In brief, PapMV nanoparticles are
constituted of PapMV coat proteins and assemble
in vitro around an RNA transcript. The Limulus Amebo-
cyte lysate (LAL) assay (Lonza, Walkersville, Maryland,
USA) was used to evaluate the levels of LPS contami-
nants that were found to be below the detection limit.
PapMV nanoparticles were characterized by electron
microscopy and dynamic light scattering as described
previously [12]. In brief, nanoparticles sizes were recorded
with a ZetaSizer Nano ZS (Malvern, Worcestershire,
United Kingdom) at 0.1 mg/ml in 10 mM Tris–HCl
pH 8.0. Water diluted PapMV nanoparticles were stained
with 3% acetate-uranyl on carbon-formvar grids then ob-
served with a FEI-TECNAI-Spirit transmission electron
microscope (FEI, Hillsboro, Oregon, USA).
Vaccination protocol
Mice, 6 to 8-week-old BALB/c (10/group), were im-
munized twice at 14-day interval by the intranasal (i.n.)
or subcutaneous (s.c.) routes with 50 μl of a formulation
containing 2.1 μg of each hemagglutinin (HA) (TIV
2009–2010 (A/Brisbane/59/2007 (H1N1), A/Brisbane/
10/2007 (H3N2), B/Brisbane/60/2008), cat #9815,
GlaxoSmithKline) alone or adjuvanted by 21 μg of
PapMV nanoparticles. Bleedings were performed at
day 0 and 28 and bronchoalveolar lavages (BAL), at
day 28 post-immunization.Antibody response quantification
BALs were performed using 700 μl of phosphate buf-
fered saline and cells were purged from the samples by
centrifugation. Blood sample were collected and centri-
fuged in BD Microtainer blood collection tubes (BD,
Mississauga, Ontario, Canada) for 2 minutes at 10 000 × g.
The harvested serums and BAL fluids were assayed for
total IgG, IgG2a serotype and IgA against TIV or IgG2a
against GST-NP by enzyme-linked immunosorbent assay
(ELISA) as described elsewhere [7,13]. GST-NP is a
C-terminal fusion of the influenza nucleoprotein to a
glutathione S-transferase (GST) protein [7]. ELISAs were
conducted by serial dilutions by two-fold steps start-
ing at 1 in 50. Results are expressed as an antibody
endpoint titer greater than threefold the background
optical density values consisting of preimmune sera or
control BAL fluids.
Mice challenge with influenza virus
Mice were challenged 2 weeks after the last immuni-
zation with 250 plaque-forming units (pfu) of A/WSN/
33(H1N1) influenza virus by 50 μl intranasal instillation.
Weight losses and symptoms were monitored for 14 days
post-infection. Symptoms are rated from 0 to 4 (no
symptoms (0), lightly spiked fur and curved back [1],
spiked fur and curved back [2], difficulty to move and
light dehydration [3], severe dehydration, lack of reflex
and ocular secretion [4]), where 4 is the highest score
and mice are euthanized. Mice that lost more than 20%
of their initial weight are also euthanized.
Statistical analysis
Data from ELISA and challenge (day 8 weight losses and
symptoms) were analyzed with a parametric ANOVA
test. Tukey’s post tests were used to compare differences
among groups of mice. Kaplan-Meier survival curves
were analysed by the log rank test. Values of *p < 0.05,
**p < 0.001 and ***p < 0.0001 were considered statistically
significant. Statistical analyses were performed using
GraphPad PRISM 5.01.
Ethics statement
All the work with animals has been done with institution
approved ethics protocol by the “Comité de Protection
des Animaux - CHUQ (CPA-CHUQ)”. The approval of
this project is found under the authorization number
2010–148.
Results and discussion
PapMV nanoparticles are composed of the recombinant
coat proteins of PapMV purified from E. coli and self-
assembled around a single-stranded RNA. Transmission
electron microscopy revealed that PapMV nanoparticles
have a filamentous rod shape structure (Figure 1A) and
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Figure 1 Structure of the PapMV nanoparticles. PapMV nanoparticles were observed with a transmission electron microscope and by
dynamic light scattering. PapMV nanoparticles have a filamentous rod-shape structure (A) with an average length of 100 nm as shown by














































































































































































Figure 2 PapMV nanoparticles improve the mucosal antibody response against TIV and NP in the lungs. Balb/C mice (10/group) were
vaccinated twice at a 14-day interval with TIV alone or adjuvanted by PapMV nanoparticles by intranasal (i.n.) or subcutaneous (s.c.) routes.
Bronchoalveolar lavages were performed at day 28 and ELISA were conducted to evaluate the levels of total IgG (A), IgG2a (B) or IgA (C) against
TIV and IgG2a against NP (D). Titers against TIV or GST-NP were not detected in the blood or BAL of PapMV nanoparticles or buffer vaccinated
mice. *P < 0.05, **P < 0.01 and ***P < 0.001.
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light scattering (Figure 1B).
To evaluate the potential of PapMV nanoparticles as
a mucosal adjuvant, mice were immunized twice at 14
days interval by either the i.n. or s.c. routes with TIV
alone or adjuvanted with PapMV nanoparticles. Anti-
bodies levels against TIV in the BAL (Figure 2) and in
the blood (Figure 3) were measured by ELISA at day 28.
We showed that TIV adjuvanted with PapMV nanoparti-
cles administered either by the i.n. or s.c. improved and
potentiate the TIV as observed by the levels of total IgG
titers directed against TIV (Figure 2A). IgG2a titers in
the BAL showed significant higher levels in the adu-
vanted group only when administered by the s.c. route
(Figure 2B). Interestingly, the group showing the highest
IgA titers in the BAL was the adjuvanted TIV admi-
nistered by the i.n. route (Figure 2C) showing clearly the
effectiveness of PapMV nanoparticles to improve the
mucosal antibody response in the lung. The ELISA also

























































































Figure 3 PapMV nanoparticles improve the systemic antibody respon
twice at a 14-day interval with TIV alone or adjuvanted with PapMV nanop
performed at day 28 and ELISA were conducted to evaluate the levels of to
Titers against TIV or GST-NP were not detected in the blood or BAL of Pap
***P < 0.001.response to the TIV antigens through a significant in-
creased in the lungs of the IgG2a titers directed to the in-
fluenza NP (Figure 2D), a highly conserved protein
through all the strains of influenza often used in expe-
rimental influenza vaccines [7,14,15]. NP has also been
identified as a key antigen to trigger cross-protection to
influenza viruses [8,16-18]. It is therefore a good strategy
to increase the immune response directed to this antigen
using PapMV nanoparticles to broaden and improve pro-
tection to this virus. Through the course of the experi-
ment, we have not notice any sign of toxicity associated
with the use of PapMV nanoparticles.
In the blood, the levels of total IgG or IgG2a were
higher than in the BAL with either route of immuniza-
tion (Figure 3). We also showed that the titers in total
IgG or IgG2a directed to TIV or GST-NP were similar
when the adjuvanted formulation was administered by
the i.n. or the s.c. route (Figure 3A-B, D). As expected,
only the adjuvanted vaccine administered by the i.n.


































































































se against TIV and NP. Balb/C mice (10/group) were vaccinated
articles by intranasal (i.n.) or subcutaneous (s.c.) routes. Bleedings were
tal IgG (A), IgG2a (B) or IgA (C) against TIV and IgG2a against NP (D).
MV nanoparticles or buffer vaccinated mice. *P < 0.05, **P < 0.01 and
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Figure 4 Mice vaccinated with PapMV nanoparticles adjuvanted TIV showed an increased protection to an influenza challenge with
influenza strain normally lethal to TIV vaccinated mice. Mice vaccinated twice with TIV adjuvanted or not by PapMV nanoparticles by
intranasal (i.n.) or subcutaneous (s.c.) routes were challenged with 250 pfu of A/WSN/1933 (H1N1) influenza virus. Mice were monitored for weight
loss (A), symptoms levels (B) and survival (C) for 14 days. Statistical analysis is applied between groups of the same immunization ways. *P < 0.05,
**P < 0.01 and ***P < 0.001.
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GST-NP were not detected in the blood or BAL of PapMV
nanoparticles or buffer vaccinated mice.
We previously showed that mice immunized s.c. with
the TIV adjuvanted with PapMV nanoparticles induced
protection against an strain of influenza that overcome
the protection induced by the TIV [8]. In this study, we
wish to validate that the adjuvanted TIV with PapMV
nanoparticles administered by the intranasal route can
also elicit this kind of protection. Therefore, we chal-
lenged vaccinated mice with A/WSN/33(H1N1), a strain
of influenza that was previously showed to overcome the
protection induced by the TIV. As expected, mice vac-
cinated with TIV by either route of immunization were
not protected and showed major weight losses (more
than 15%) (Figure 4A) and strong symptoms (Figure 4B);
while mice immunized by the i.n. route with the PapMV
adjuvanted TIV showed a weight increased (Figure 4A)
without any symptoms during infection (Figure 4B).
Mice immunized with the same formulation by the s.c.
route lost 7% of their initial weight and showed mild
symptoms at the infection peak (day 8) (Figure 4A,B).
Finally, only mice immunized by the i.n. route with
the adjuvanted TIV formulation showed 100% survival
(Figure 4C). The PapMV adjuvanted i.n. vaccine gen-
erated a robust protection to the infection by an in-
fluenza strain normally lethal to TIV vaccinated mice.PapMV nanoparticles is therefore an efficient mucosal
adjuvant with strong potential for its used in human.
Conclusions
In conclusion, we demonstrate for the first time that
PapMV nanoparticle is an effective and potent mucosal
adjuvant for vaccination against a respiratory disease.
This technology fulfills an important medical need for a
safe mucosal adjuvant that broadens the protection of
the TIV.
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